2160.HK Stock Analysis
21
Uncovered
Microport Cardioflow Medtech Corp is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Market cap $B
0.207
Dividend yield
—
Shares outstanding
2 366.05 B
MicroPort CardioFlow Medtech Corp. operates as a holding company with interest in developing medical devices. The company is headquartered in Shanghai, Shanghai and currently employs 526 full-time employees. The company went IPO on 2021-02-04. The firm is mainly engaged in the development and commercialization of transcatheter and surgical solutions for valvular heart diseases. The firm's main products include the first-generation transcatheter aortic heart valve implantation (TAVI) product VitaFlow and the second-generation TAVI product VitaFlow II. The firm mainly conducts business within the domestic market.